Large-Scale Protein Production Service

The global biopharmaceutical and life sciences industries are witnessing a surge in demand for pure, bioactive proteins, driven by advancements in drug discovery, personalized medicine, and diagnostic development. Since 2022, businesses such as recombinant protein production , customized protein expression, and GMP protein synthesis have continued to grow, reflecting the critical need for proteins with precise folding, post-translational modifications, and functional activity to support applications such as therapeutic antibody development, vaccine research, and CRISPR-based technologies.

As a leader in protein services, Creative BioMart addresses this demand through end-to-end solutions tailored for research and commercial use. Unlock the full potential of your protein research and development with our cutting-edge large-scale protein production services—where high purity meets high volume, and innovation drives success.

2,000L

Fermentation capacity

98%+

Pure

300 g

Production in a single project

3,000+

Proteins delivered

Background

Historical Development

The journey of protein production has transformed dramatically since its early laboratory-scale beginnings. In the mid-20th century, proteins were isolated directly from natural sources, a process limited by low yields and high costs. The advent of recombinant DNA technology in the 1970s revolutionized the field, enabling scientists to engineer organisms like E. coli and yeast for protein synthesis. By the 2000s, advancements in mammalian cell culture systems and continuous fermentation processes addressed challenges in producing complex proteins with post-translational modifications, fueling the rise of biologics like monoclonal antibodies and vaccines. Today, industrial-scale bioreactors and AI-driven optimization tools ensure high-purity yields for therapeutic and diagnostic applications.

Key biotechnological breakthroughs have propelled large-scale protein production. The development of CRISPR-based gene editing streamlined cell line engineering, while single-use bioreactor systems reduced contamination risks and costs. Innovations in fed-batch and perfusion fermentation further enhanced scalability for GMP-grade manufacturing. As a pioneer in this space, Creative BioMart integrates these advancements into its workflows, offering tailored solutions like stable cell line development and multi-gram-scale purification. Our expertise in insect cell-baculovirus systems and fusion tag technologies ensures bioactive outputs for applications ranging from structural biology to mRNA vaccine development.

Advantages

Scalability: Flexible Solutions for Varied Demands

Large-scale protein production delivers quantities from milligrams to hundreds of grams, supporting research, clinical trials, and commercial therapeutics. Advanced bioreactor systems and flexible expression platforms enable rapid scaling for applications like mRNA vaccines and antibody therapies, ensuring consistent output for high-volume needs.

Efficiency: Speed and Precision in Production

AI-optimized workflows and automated purification technologies reduce turnaround times. High-density fermentation and real-time analytics maximize yield while maintaining batch consistency—critical for fast-paced projects such as pandemic-response biologics or CRISPR enzyme supply.

Purity: Essential for Critical Applications

Proteins with ≥98% purity (verified by HPLC/SDS-PAGE) are achieved through multi-step chromatography and endotoxin removal. Rigorous quality checks ensure bioactivity and structural integrity, meeting standards for drug development, structural biology, and GMP-compliant therapeutics.

Cost-Effectiveness: Affordable High-Quality Output

Bulk production and optimized workflows cut costs by up to 40% versus in-house methods. Economies of scale, reduced waste, and flexible pricing models make premium proteins accessible for startups and academic labs, supporting affordable biosimilar and oncology research.

Applications

Drug Development: Accelerating Therapeutic Innovations

Large-scale recombinant protein production is indispensable for advancing protein-based therapeutics, including monoclonal antibodies, cytokines, and enzyme replacements. Our GMP-compliant services ensure lot-to-lot consistency and endotoxin-free outputs , supporting applications in oncology, autoimmune diseases, and rare genetic disorders.

Structural Biology: Precision for Molecular Insights

High-purity recombinant proteins are essential for structural biology techniques like X-ray crystallography, cryo-EM, and NMR spectroscopy. Our optimized E. coli and insect cell platforms deliver structurally validated proteins, aiding in drug target validation and rational drug design for kinases, GPCRs , and viral proteases.

Proteomics: Powering Comprehensive Protein Analysis

Large-scale protein production supports proteomics research by providing standardized, batch-consistent reagents for studying protein expression, interactions, and post-translational modifications (PTMs). Our services enable the generation of isotope-labeled proteins for quantitative mass spectrometry, affinity-tagged proteins for interactome mapping, and modified variants to model cellular signaling pathways.

Biopharmaceuticals: Meeting Industry Demand

The biopharmaceutical sector relies heavily on recombinant proteins for vaccines, biosimilars, and enzyme therapies. Our platforms—including CHO cell-based systems and yeast expression —deliver high-yield, cost-effective production of complex targets like viral antigens, clotting factors, and fusion proteins.

Service Details

Core Services

Bacteria

• Transformed bacterial culture for large-scale fermentation, up to 2,000L.
• Provides homogeneous recombinant proteins, over 98% pure, for crystallization, and partially purified recombinant proteins, over 70% pure.
• Provides large quantities of protein, up to several grams.

Yeast

• Yeast culture up to 2,000L for large-scale fermentation.
• Provides homogeneous recombinant proteins, over 98% pure, for crystallization.
• Provides partially purified recombinant proteins, over 70% pure.
• Provides large quantities of protein, up to grams.

Baculovirus-Insect Cells

• High titer recombinant baculovirus stock carrying the customer's gene.
• Provides homogeneous recombinant proteins, over 98% pure, for crystallization.
• Provides partially purified recombinant proteins, over 70% pure.
• Provides a large-scale protein production option, up to few hundreds of mg, using insect cells and a wave mixer system.

Mammalian Cells

• Provides one single system for the production of final homogeneous recombinant proteins; from gene synthesis to expression; for orders of up to 100mg.
• Permits transient expression of customers' proteins of interest, up to 10mg in 10 days.
• Provides conditioned media and cell pellets from stable cell lines, up to 500L, using a wave mixer system.

Service Delivery & Submission Guidelines

• Submission Requirements

• Protein Specifications : Provide sequence (FASTA/GenBank), desired host system, post-translational modifications, and required quantity (mg to kg).
• Cloning Material : Submit plasmid DNA, synthetic genes, or authorize us to synthesize codons optimized for high-yield expression.
• Special Requests : Specify tags (His, FLAG), buffer conditions, or custom purity/activity validations.

• Delivery Details

• Turnaround : 6-8 weeks standard (4 weeks for fast-track protein services). Urgent projects prioritized.
• Formats : Lyophilized or liquid (PBS, Tris-HCl) with stability data. Storage: -80°C or 4°C.
• Quality Docs : SDS-PAGE/HPLC purity reports, endotoxin levels (<1 EU/µg), and activity certificates.
• Shipping : Global express delivery (dry ice or cold chain) with real-time tracking.
• Post-Delivery Support : Free solubility/activity troubleshooting for 30 days .

Why Choose Us?

Expertise & Experience. Over 10 years of experience delivering high-quality proteins. Proven track record with thousands of successful projects.

Advanced Technology. State-of-the-art platforms including fermentors, wave mixers, and bioreactors. Scalable solutions from milligrams to hundreds of grams.

Quality & Purity. High-purity proteins (over 98% for crystallization, over 70% for partially purified). Stringent quality control ensures reliability.

Custom Solutions. Fully customizable services tailored to your specific needs, from gene synthesis to protein purification.

Efficient Turnaround. Optimized processes for fast delivery without compromising quality. Meet your deadlines efficiently.

Exceptional Support. Dedicated customer support throughout your project. Our team is always ready to assist and ensure a seamless experience.

Case Study

Case 1: Large-Scale Production of Functional Olfactory Receptor OR17-4

Research Background : Olfactory receptors (ORs) are critical for understanding the molecular mechanisms of olfaction. However, large-scale production of functional ORs has been challenging due to their complex structures and low expression levels.

Methods : Researchers developed a mammalian expression system using HEK293S cells to produce and purify the human olfactory receptor OR17-4. The system utilized a tetracycline-inducible promoter and bioreactor suspension culture to scale up production.

Results : The study achieved production yields of over 10 mg of monomeric hOR17-4 receptor per liter of culture medium. The purified receptor exhibited specific binding to odorants lilial and floralozone, as confirmed by surface plasmon resonance and calcium ion mobilization assays.

Conclusion : This scalable production system enables the generation of large quantities of functional OR17-4, facilitating structural and functional analyses and paving the way for OR-based biosensor development.

Fig1. Construction of hOR17-4-inducible HEK293S GnT1−/− cell lines for use in liquid bioreactor culture. (Cook, et al. , 2009)

Case 2: Large-Scale Production of Penicillin G Acylase in Pichia pastoris

Research Background : Penicillin G acylase of Escherichia coli (PGAEc) is a valuable enzyme used in the hydrolytic production of β-lactam nuclei and the synthesis of semi-synthetic penicillins. Efficient bacterial expression systems have been developed, but this study explores the potential of yeast expression systems, specifically Pichia pastoris , for large-scale production.

Methods : The leaderless gene encoding PGAEc was cloned under the control of the AOX1 promoter in Pichia pastoris X-33. The intracellular overproduction of heterologous PGAEc (hPGAEc) was evaluated in a 10-liter stirred bioreactor using high-cell density, fed-batch cultures with different transient phase profiles.

Results : Under optimal conditions, the average volumetric activity of 25,900 U/L was achieved. The hPGAEc was purified and characterized, showing modified traits compared to wild-type PGAEc. The enzyme exhibited reduced activity (49%) but improved synthesis/hydrolysis ratios for cephalexin production.

Conclusion : The study demonstrates the feasibility of using Pichia pastoris for large-scale production of PGAEc, achieving high volumetric activity and enzyme yield.

Fig2. The effect of transient phase profile on hPGAEc production in fed-batch cultures of the strain P. pastoris X-33(pPIC-PA1). (Maresová, et al. , 2010)

Case 3: Expression of Botulinum Neurotoxin Serotype B Hc Protein Using a 293E Expression System

Research Background : Recombinant Hc proteins of botulinum neurotoxins are crucial for vaccine development. Traditionally, Escherichia coli and yeast systems have been used, but this study explores the use of a 293E mammalian cell expression system for producing the Hc domain of BoNT serotype B (BHc).

Methods : The Hc gene of BoNT serotype B was cloned into a plasmid (pABE293SBHc) and expressed in a 293E cell line. The recombinant BHc protein was purified and evaluated for immunogenicity and protective efficacy in mice.

Results : The 293E system produced high levels of soluble, secreted BHc protein, which was specifically recognized by anti-BoNT/B sera and exhibited ganglioside binding activity. Mice immunized with BHc formulated with Alhydrogel showed strong immune responses and protection against BoNT/B challenge.

Conclusion : The 293E expression system efficiently produces functional BHc protein suitable for experimental vaccine development, offering an alternative to traditional bacterial and yeast systems.

Fig3. Enzyme-linked immunosorbent assay of binding activity of the recombinant BHc protein to ganglioside (GT1b). (Yu, et al. , 2015)

Customer Testimonials

"Scaling our ADC payload from 10mg to 500g using their CHO platform was flawless. Zero deviations in 12 batches. A leader in industrial-scale antibody fragment production."

-Dr. Emily Chen, Director of Manufacturing Operations | Global Biologics Manufacturer

"GMP-grade cytokines for commercial launch met 98.5% purity with 30% faster timelines. Redefined excellence in high-compliance protein manufacturing."

-Mr. James O’Connor, Head of Bioprocess Engineering | Industrial Biotech Solutions

“Insoluble kinase targets achieved 85% solubility via their baculovirus system. Cut development cycles by 6 months. Masterclass in industrial enzyme optimization.”

-Dr. Hiroshi Tanaka, VP of Technical Development | Enzyme Production Corp.

"Produced 5kg of Omicron antigen in 8 weeks using their 2,000L bioreactors. Unmatched in rapid, large-scale vaccine protein services for pandemic response."

-Ms. Fatima Al-Mansoori, Operations Director | Vaccine Manufacturing Hub

"Perfusion fermentation reduced bispecific antibody costs by 45%, accelerating commercialization. A benchmark for cost-efficient therapeutic protein production."

-Dr. Lucas Weber, CMC Lead | Oncology Biotherapeutics Group

"Selected their services after auditing 8 vendors. FDA-ready documentation and <0.05 EU/mg endotoxin control set the bar for regulatory-driven protein manufacturing."

-Ms. Anika Patel, Global QA Director | Pharma Compliance Network

FAQs

• Q: What production scales do you support for recombinant proteins?

  A: We offer large-scale protein production services from milligrams to kilograms, adaptable for research, preclinical studies, and commercial biomanufacturing. Flexible platforms (CHO, E. coli , yeast) ensure seamless scaling to meet demands like antibody-drug conjugates or vaccine antigens.

• Q: How do you ensure cost-efficiency in protein expression?

  A: Our high-yield fermentation systems and bulk pricing models reduce costs by up to 50%. AI-driven strain optimization minimizes resource waste, while shared-batch programs help startups access cost-effective recombinant protein services without upfront investments.

• Q: What quality control standards are applied?

  A: Proteins undergo rigorous testing: ≥98% purity (HPLC/SDS-PAGE), endotoxin levels <0.1 EU/mg, and functional validation (e.g., SPR, ELISA). GMP-compliant manufacturing options include full traceability and ICH-aligned documentation for clinical applications.

• Q: Can you handle complex post-translational modifications?

  A: Yes. Our mammalian (HEK293, CHO) and insect cell platforms enable glycosylation, phosphorylation, and disulfide bond formation. Ideal for monoclonal antibodies, viral envelope proteins, and therapeutic protein production requiring native-like folding.

• Q: What turnaround times can we expect?

  A: Standard projects take 4-6 weeks. Fast-track protein expression services (3 weeks) leverage pre-optimized vectors and high-density fermentation. Urgent vaccine projects are prioritized with dedicated production lines.

References:

1. Cook BL.; et al . Large-scale production and study of a synthetic G protein-coupled receptor: human olfactory receptor 17-4. Proc Natl Acad Sci U S A . 2009;106(29):11925-11930.
2. Maresová H.; et al . Heterologous expression of leader-less pga gene in Pichia pastoris: intracellular production of prokaryotic enzyme. BMC Biotechnol . 2010;10:7.
3. Yu Y.; et al . Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Hum Vaccin Immunother . 2015;11(2):468-473.